Alembic Pharma gets 1 observation from USFDA for Karkhadi unit
New Delhi: Alembic Pharmaceuticals said the US health regulator has issued one observation on inspection of the company's Karkhadi facility in Gujarat.
As per a BSE filing by Alembic, USFDA conducted the inspection at active pharmaceutical ingredient (API) facility at Karkhadi from May 14-18, 2018.
"This was a scheduled inspection and at the end of the inspection, USFDA issued a Form 483 with one observation," the company said.
Alembic is preparing the response to the observation, which will be submitted to the United States Food and Drug Administration (USFDA) shortly, it said.
As per USFDA, Form 483 is issued at the conclusion of an inspection, notifying a company's management of objectionable conditions at the facility.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd